Liminatus Pharma, Inc. (LIMN)
3.76
+0.07
(+1.90%)
USD |
NASDAQ |
Oct 09, 16:00
3.78
+0.02
(+0.53%)
After-Hours: 20:00
Liminatus Pharma Enterprise Value : -1.490M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | -1.490M |
| October 08, 2026 | -1.492M |
| October 07, 2026 | -1.488M |
| October 06, 2026 | -1.492M |
| October 05, 2026 | -1.485M |
| October 02, 2026 | -1.487M |
| October 01, 2026 | -1.491M |
| September 30, 2026 | -1.491M |
| September 29, 2026 | -1.487M |
| September 28, 2026 | -1.479M |
| September 25, 2026 | -1.481M |
| September 24, 2026 | -1.481M |
| September 23, 2026 | -1.484M |
| September 22, 2026 | -1.483M |
| September 21, 2026 | -1.493M |
| September 18, 2026 | -1.497M |
| September 17, 2026 | -1.499M |
| September 16, 2026 | -1.50M |
| September 15, 2026 | -1.496M |
| September 14, 2026 | -1.496M |
| September 11, 2026 | -1.497M |
| September 10, 2026 | -1.493M |
| September 09, 2026 | -1.497M |
| September 08, 2026 | -1.494M |
| September 04, 2026 | -1.492M |
| Date | Value |
|---|---|
| September 03, 2026 | -1.492M |
| September 02, 2026 | -1.489M |
| September 01, 2026 | -1.493M |
| August 31, 2026 | -1.488M |
| August 28, 2026 | -1.480M |
| August 27, 2026 | -1.476M |
| August 26, 2026 | -1.476M |
| August 25, 2026 | -1.471M |
| August 24, 2026 | -1.47M |
| August 21, 2026 | -1.459M |
| August 20, 2026 | -1.448M |
| August 19, 2026 | -1.450M |
| August 18, 2026 | -1.429M |
| August 17, 2026 | -1.416M |
| August 14, 2026 | -1.418M |
| August 13, 2026 | -1.407M |
| August 12, 2026 | -1.453M |
| August 11, 2026 | -1.450M |
| August 10, 2026 | -1.444M |
| August 07, 2026 | -1.459M |
| August 06, 2026 | -1.464M |
| August 05, 2026 | -1.457M |
| August 04, 2026 | -1.442M |
| August 03, 2026 | -1.447M |
| July 31, 2026 | -1.459M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
| Savara, Inc. | 867.94M |
| Vericel Corp. | 1.984B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.407M |
| Total Expenses (Quarterly) | 1.407M |
| EPS Diluted (Quarterly) | -72.70 |
| Earnings Yield | -28.57K% |
| Normalized Earnings Yield | -14147.98 |